Therapeutics News and Research

RSS

CMC Biologics wins Life Science Leader CMO Leadership award for highest standards of quality, reliability

CMC Biologics, a leading global contract manufacturing organization known for technical excellence and customer satisfaction in biopharmaceutical development and commercial manufacture of protein based therapeutics, was recognized again in 2014 for innovation, quality and reliability by Life Science Leader at an awards ceremony at DCAT Week14 in New York last month.

3 Apr 2014

Expert in gene therapy joins The Children's Hospital of Philadelphia

Beverly L. Davidson, Ph.D., a nationally prominent expert in gene therapy, is joining The Children's Hospital of Philadelphia (CHOP) today.

2 Apr 2014

Leading researchers to convene at 4th Annual Traumatic Brain Injury Conference

The world's leading researchers in the field of traumatic brain injury research are meeting on April 16 & 17, 2014 in Washington DC for the 4th Annual Traumatic Brain Injury Conference.

2 Apr 2014

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose).

2 Apr 2014

UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

UCLA Scientist Dr. Ira Kurtz has received a $3 million gift from the Donald T. Sterling Foundation to fund research on the structural properties of key proteins in the kidney that affect its function in health and disease.

2 Apr 2014

FORMA Therapeutics signs second strategic collaboration and option agreement with Celgene

FORMA Therapeutics, an innovative R&D organization in pursuit of ground-breaking medicines in oncology and other therapeutic areas, today announced a second strategic collaboration and option agreement with Celgene Corporation, a leader in addressing high unmet medical needs.

1 Apr 2014

Antibe Therapeutics closes previously announced non-brokered private placement

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") has closed its previously announced non-brokered private placement raising gross proceeds of $3,015,398 (the "Offering") on the sale of 5,025,664 Common Shares of the Corporation.

1 Apr 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

e-Therapeutics plc announced today interim results from its phase Ia UK study evaluating the safety, dosing and anti-tumour activity of ETS2101 (dexanabinol) in patients with advanced solid tumours.

31 Mar 2014

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Integral Molecular, a leader in membrane protein antibody discovery, announces the issuance of a new patent protecting the use of Lipoparticles for eliciting antibodies against membrane protein targets.

29 Mar 2014

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.

29 Mar 2014

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

An international research group led by Arizona State University professor Qiang "Shawn" Chen has developed a new generation of potentially safer and more cost-effective therapeutics against West Nile virus and other pathogens.

29 Mar 2014

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Halozyme Therapeutics, Inc. announced today that the European Commission has approved Roche's new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma.

28 Mar 2014

Researchers find new drug target for mitochondrial dysfunction

Mitochondria, long known as "cellular power plants" for their generation of the key energy source adenosine triphosphate (ATP), are essential for proper cellular functions. Mitochondrial defects are often observed in a variety of diseases, including cancer, Alzheimer's disease, and Parkinson's disease, and are the hallmarks of a number of genetic mitochondrial disorders whose manifestations range from muscle weakness to organ failure. Despite a fairly strong understanding of the pathology of such genetic mitochondrial disorders, efforts to treat them have been largely ineffective.

28 Mar 2014

'Mini heart' invented to aid blood flow through venous segments

George Washington University researcher Narine Sarvazyan, Ph.D., has invented a new organ to help return blood flow from veins lacking functional valves. A rhythmically contracting cuff made of cardiac muscle cells surrounds the vein acting as a 'mini heart' to aid blood flow through venous segments. The cuff can be made of a patient's own adult stem cells, eliminating the chance of implant rejection.

28 Mar 2014

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

RuiYi, Inc. announced today a $15 million Series B financing by existing investors: 5AM Ventures, Versant Ventures, Apposite Capital, SR One, the independent corporate healthcare venture capital fund of GlaxoSmithKline, Merck Serono Ventures, the strategic corporate venture fund of Merck Serono, and Aravis SA.

27 Mar 2014

New drug multiplies analgesic effect of opioids without increasing constipation

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine.

27 Mar 2014

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Senhwa Biosciences, Inc. announced today that results from research with its first-in-class Pol I inhibitor, CX-5461, will be presented at the 2014 American Association for Cancer Research (AACR) annual meeting held on April 5-9 in San Diego, CA.

27 Mar 2014

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

From Baxter International Inc. 27 Mar 2014

Therapeutics News and Research

CMC Biologics wins Life Science Leader CMO Leadership award for highest standards of quality, reliability

Expert in gene therapy joins The Children's Hospital of Philadelphia

Leading researchers to convene at 4th Annual Traumatic Brain Injury Conference

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

FORMA Therapeutics signs second strategic collaboration and option agreement with Celgene

Antibe Therapeutics closes previously announced non-brokered private placement

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

e-Therapeutics announces interim results from ETS2101 phase Ia trial for advanced solid tumours

Integral Molecular announces new patent protecting use of lipoparticles for eliciting antibodies against protein targets

Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Researchers develop potentially safer and more cost-effective therapeutics against West Nile virus

EC approves Roche's SC formulation of MabThera for common forms of non-Hodgkin lymphoma

Researchers find new drug target for mitochondrial dysfunction

'Mini heart' invented to aid blood flow through venous segments

RuiYi declares $15M Series B financing to advance monoclonal antibodies targeting GPCR receptors

New drug multiplies analgesic effect of opioids without increasing constipation

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Baxter plans to create two independent global healthcare companies

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News